Lead Product(s) : Pancreatin
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pancreatin is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Exocrine Pancreatic Insufficiency.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 11, 2012
Lead Product(s) : Pancreatin
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
